The International Adjuvant Lung Cancer Trial (IALT) analysis showed that patients with ERCC1 protein negative tumors have better adjuvant cisplatin‐based chemotherapy results compared to patients with ERCC1 protein positive tumors.22 The gene discussed is ERCC1; the disease is lung cancer.